Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged >65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices (vol 68, pg 1074, 2019)

被引：0
|
作者：
Bennett, Nancy [1 ]
Farley, Monica [2 ,3 ]
机构：
[1] Univ Rochester, Med Ctr, Rochester, NY 14627 USA
[2] Vet Affairs Med Ctr, Decatur, GA 30033 USA
[3] Emory Univ, Dept Med, Atlanta, GA 30322 USA
来源：
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT | 2020年 / 68卷 / 51-52期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：1195 / 1195
页数：1
相关论文
共 50 条
  • [21] Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among US Adults: Updated Recommendations of the Advisory Committee on Immunization Practices-United States, 2022
    Kobayashi, Miwako
    Farrar, Jennifer L.
    Gierke, Ryan
    Britton, Amadea
    Childs, Lana
    Leidner, Andrew J.
    Campos-Outcalt, Doug
    Morgan, Rebecca L.
    Long, Sarah S.
    Talbot, H. Keipp
    Poehling, Katherine A.
    Pilishvili, Tamara
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2022, 71 (04): : 109 - 117
  • [22] Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China
    Mo, Xiuting
    Tobe, Ruoyan Gai
    Liu, Xiaoyan
    Mori, Rintaro
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (11) : E353 - E361
  • [23] Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
    Gouveia, Miguel
    Jesus, Goncalo
    Ines, Monica
    Costa, Joao
    Borges, Margarida
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (04) : 850 - 858
  • [24] Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK
    Jiang, Yiling
    Gauthier, Aline
    Keeping, Sam
    Carroll, Stuart
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (06) : 913 - 927
  • [25] Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy
    Garcia Garrido, Hannah M.
    Vollaard, Albert
    D'Haens, Geert R.
    Spuls, Phyllis I.
    Bemelman, Frederike J.
    Tanck, Michael W.
    de Bree, Godelieve J.
    Meek, Bob
    Grobusch, Martin P.
    Goorhuis, Abraham
    VACCINES, 2022, 10 (05)
  • [26] Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older
    Jackson, Lisa A.
    Gurtman, Alejandra
    van Cleeff, Martin
    Frenck, Robert W.
    Treanor, John
    Jansen, Kathrin U.
    Scott, Daniel A.
    Emini, Emilio A.
    Gruber, William C.
    Schmoele-Thoma, Beate
    VACCINE, 2013, 31 (35) : 3594 - 3602
  • [27] Immunogenicity of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine in people living with HIV on combination antiretroviral therapy
    Garrido, Hannah M. Garcia
    Schnyder, Jenny L.
    Haydari, Beheshta
    Vollaard, Albert M.
    Tanck, Michael W. T.
    de Bree, Godelieve J.
    Meek, Bob
    Grobusch, Martin P.
    Goorhuis, Abraham
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2022, 60 (02)
  • [28] Predictors of serological non-response to the 13-valent pneumococcal conjugate vaccine followed by the 23-valent polysaccharide vaccine among adults living with HIV
    Tinggaard, Michaela
    Slotved, Hans-Christian
    Jorgensen, Charlotte Svaerke
    Kronborg, Gitte
    Benfield, Thomas
    VACCINE, 2023, 41 (30) : 4414 - 4421
  • [29] THE COST-EFFECTIVENESS ANALYSIS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) AND 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) IN TAIWAN
    Wu, D. B. C.
    Chang, C. J.
    Chien, L.
    Fang, H. C. H.
    Roberts, C. S.
    VALUE IN HEALTH, 2012, 15 (07) : A602 - A602
  • [30] A public health and budget impact analysis of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK
    Jiang, Yiling
    Gauthier, Aline
    Keeping, Sam
    Carroll, Stuart
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (06) : 901 - 911
12345